6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT ID: NCT02140060

Last Updated: 2015-12-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 327 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2014-11-30

Brief Summary

The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the unfixed combination of TRAVATAN Z® plus AZOPT® in lowering intraocular pressure (IOP).

Detailed Description

This study was divided into two phases conducted in sequence. Phase I was the Screening/Eligibility Phase, which included a Screening Visit, followed by two Eligibility Visits. Phase II was the randomized, double-masked, 6-week Treatment Phase which included on-therapy visits at Week 2 and Week 6. Travoprost was administered in 1 of 3 concentration levels (A-C), where A=lowest and C=highest.

Conditions

Glaucoma; Ocular Hypertension

Keywords

Glaucoma; Ocular; Hypertension; OAG; POAG; OHT

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

TravA/Brinz

Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks

Group Type: EXPERIMENTAL

Dose Level A / Brinzolamide 1% ophthalmic suspension

Intervention Type: DRUG

Fixed combination

Travoprost solution vehicle

Intervention Type: DRUG

Inactive ingredients used for masking purposes

TravB/Brinz

Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks

Group Type: EXPERIMENTAL

Dose Level B / Brinzolamide 1% ophthalmic suspension

Intervention Type: DRUG

Fixed combination

Travoprost solution vehicle

Intervention Type: DRUG

Inactive ingredients used for masking purposes

TravC/Brinz

Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks

Group Type: EXPERIMENTAL

Dose Level C / Brinzolamide 1% ophthalmic suspension

Intervention Type: DRUG

Fixed combination

Travoprost solution vehicle

Intervention Type: DRUG

Inactive ingredients used for masking purposes

AZOPT

Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks

Group Type: ACTIVE_COMPARATOR

Brinzolamide 1% ophthalmic suspension AZOPT®

Intervention Type: DRUG

Travoprost solution vehicle

Intervention Type: DRUG

Inactive ingredients used for masking purposes

TRAV Z

Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks

Group Type: ACTIVE_COMPARATOR

Travoprost 0.004% ophthalmic solution TRAVATAN Z®

Intervention Type: DRUG

Brinzolamide suspension vehicle

Intervention Type: DRUG

Inactive ingredients used for masking purposes

TRAV Z + AZOPT

Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks

Group Type: ACTIVE_COMPARATOR

Brinzolamide 1% ophthalmic suspension AZOPT®

Intervention Type: DRUG

Travoprost 0.004% ophthalmic solution TRAVATAN Z®

Intervention Type: DRUG

Interventions

Dose Level A / Brinzolamide 1% ophthalmic suspension

Fixed combination

Intervention Type: DRUG

Dose Level B / Brinzolamide 1% ophthalmic suspension

Fixed combination

Intervention Type: DRUG

Dose Level C / Brinzolamide 1% ophthalmic suspension

Fixed combination

Intervention Type: DRUG

Brinzolamide 1% ophthalmic suspension AZOPT®

Intervention Type: DRUG

Travoprost 0.004% ophthalmic solution TRAVATAN Z®

Intervention Type: DRUG

Travoprost solution vehicle

Inactive ingredients used for masking purposes

Intervention Type: DRUG

Brinzolamide suspension vehicle

Inactive ingredients used for masking purposes

Intervention Type: DRUG

Other Intervention Names

AZOPT®; TRAVATAN Z®

Eligibility Criteria

Inclusion Criteria

• Diagnosed with open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) or ocular hypertension;
• IOP within the protocol-specified range at both the Eligibility 1 and 2 Visits. Mean IOP must not be >36 mmHg at any time point;
• Able to understand and sign an informed consent form;

Exclusion Criteria

• Woman of childbearing potential who is currently pregnant, intends to become pregnant during the study period, breastfeeding, or not using adequate birth control methods to prevent pregnancy throughout the study;
• Unable to discontinue all IOP-lowering ocular medication(s) per the appropriate washout schedule prior to the E1 Visit;
• Chronic, recurrent or severe inflammatory eye disease;
• Ocular trauma within the past 6 months prior to the Screening Visit;
• Ocular infection or ocular inflammation within the past 3 months prior to the Screening Visit;
• Clinically relevant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment;
• Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to approximately 0.60 logMAR, 20/80 Snellen, or 0.25 decimal);
• Other ocular pathology (including severe dry eye) that may, in the opinion of the Investigator, preclude the administration of a topical prostaglandin analogue or topical carbonic anhydrase inhibitor;
• Intraocular surgery within the past 6 months prior to the Screening Visit;
• Ocular laser surgery within the past 3 months prior to the Screening Visit;
• Any abnormality preventing reliable applanation tonometry;
• Any other conditions including severe illness which would make the subject, in the opinion of the Investigator, unsuitable for the study;
• History of hepatic or renal disease that would preclude the safe administration of a carbonic anhydrase inhibitor (CAI) in the opinion of the Investigator;
• Hypersensitivity to prostaglandin analogues, topical or oral CAIs, sulfonamide derivatives, or to any component of the study medications in the opinion of the Investigator;
• Recent (within 4 weeks of the Eligibility 1 Visit) use of high dose (> 1 g daily) salicylate therapy;
• Use of any additional topical or systemic ocular hypotensive medication during the study;
• Concurrent use of glucocorticoids administered by any route;
• Less than 30 days stable dosing regimen before the Screening Visit of any medications (excluding the IOP-lowering treatments) or substances administered by any route and used on a chronic basis that may affect IOP (ie, β adrenergic blocking agents);
• Therapy with another investigational agent within 30 days prior to the Screening Visit;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alcon Research

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sr. Clinical Manager, GCRA, Pharma

Role: STUDY_DIRECTOR

Alcon Research

Countries

United States

Other Identifiers

C-14-003

Identifier Type: -

Identifier Source: org_study_id